[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbZj5PxE9gGLTJiTa5QQM-ZkIvfV7xpE57vQ3wbe0ies":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Universitätsklinikum Hamburg-Eppendorf",[4],408,false,81,21,3306514,344,[13,16,18,21,24,27,29,32],{"name":14,"count":15},"Airway Management",14,{"name":17,"count":15},"Stroke",{"name":19,"count":20},"Depression",11,{"name":22,"count":23},"Schizophrenia",10,{"name":25,"count":26},"Anesthesia",9,{"name":28,"count":26},"Multiple Myeloma",{"name":30,"count":31},"Multiple Sclerosis",8,{"name":33,"count":31},"Postoperative Complications",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04291261","Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease","2024-06-24","Uvadex",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03333187","Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability","2024-10-07","Ruxolitinib continuous therapy",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT02170090","Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer","2025-12","Gemcitabine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05727267","A Heterologous Protein Prime\u002FMVA Boost Therapeutic Hepatitis B Vaccine Candidate","2026-02","HEPLISAV B; TherVacB",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03104842","Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","2026-05","Isatuximab",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT04232241","Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia","2026-11-22","Allogeneic Stem Cell Transplantation",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT02066220","International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","2026-12","Reduced-intensity maintenance chemotherapy",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05853965","Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma","2027-04","Belantamab mafodotin, Venetoclax",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05959421","Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure","2027-12","ERVEBO®",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04448028","Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial","2028-02","Esomeprazole 20mg",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,117,155,178,196,220,238,256,274,312,350,368,386,408,426,444,466,488,512,585,606,624,650,675,701,719,747,765,783,810,828,854,872,899,917,942,967,994,1012,1037,1062,1080,1098,1116,1143,1161,1197,1215,1233,1251,1269,1287,1305,1323,1341,1359,1377,1395,1422,1440,1458,1482,1509,1527,1553,1582,1600,1618,1636,1661,1686,1709,1732,1756,1782,1800,1818,1836,1862,1885,1911,1935,1953,1971,1996,2014,2038,2063,2081,2108,2126,2150,2186,2213,2239,2261,2283,2305,2327,2349,2371,2393,2420,2438,2456,2485,2503,2529,2547,2565,2583,2601,2619,2637,2655,2673,2701,2726,2749,2772,2798,2816,2841,2864,2891,2916],{"intervention":84,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":115},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":83},[107],{"nctId":81,"briefTitle":82,"status":108,"phases":109,"primaryCompletion":83,"completion":83,"start":110,"enrollment":111,"conditions":112,"interventions":114},"RECRUITING",[90],"2021-04-22",476,[113],"Liver Cirrhosis",[84],{"trials":116,"activeCount":98},[],{"intervention":118,"totalTrials":119,"cells":120},"Capecitabine",2,{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":139,"PHASE4":151,"NA":153},{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[127],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":94,"conditions":134,"interventions":137},"NCT01759238","Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer","TERMINATED",[88],"2014-10","2013-05",[135,136],"Colorectal Cancer","Metastases",[118,138],"Bevacizumab",{"trials":140,"activeCount":94,"soonestReadout":48},[141],{"nctId":46,"briefTitle":47,"status":142,"phases":143,"primaryCompletion":48,"completion":48,"start":144,"enrollment":145,"conditions":146,"interventions":149},"ACTIVE_NOT_RECRUITING",[89],"2014-04",789,[147,148],"Cholangiocarcinoma","Gall Bladder Carcinoma",[49,150,118],"Cisplatin",{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":174,"NA":176},{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"trials":162,"activeCount":98},[],{"trials":164,"activeCount":94,"soonestReadout":78},[165],{"nctId":76,"briefTitle":77,"status":166,"phases":167,"primaryCompletion":78,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NOT_YET_RECRUITING",[89],"2028-06","2026-06",70,[172],"Ebola Vaccine",[79,79],{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"intervention":49,"totalTrials":94,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":192,"NA":194},{"trials":181,"activeCount":98},[],{"trials":183,"activeCount":98},[],{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":94,"soonestReadout":48},[188],{"nctId":46,"briefTitle":47,"status":142,"phases":189,"primaryCompletion":48,"completion":48,"start":144,"enrollment":145,"conditions":190,"interventions":191},[89],[147,148],[49,150,118],{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":216,"NA":218},{"trials":199,"activeCount":98},[],{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"trials":205,"activeCount":94,"soonestReadout":68},[206],{"nctId":66,"briefTitle":67,"status":142,"phases":207,"primaryCompletion":68,"completion":68,"start":208,"enrollment":209,"conditions":210,"interventions":212},[88,89],"2014-06",360,[211],"Brain Tumors",[69,213,214,215],"Maintenance chemotherapy","Induction Chemotherapy","Vinblastin Maintenance",{"trials":217,"activeCount":98},[],{"trials":219,"activeCount":98},[],{"intervention":213,"totalTrials":94,"cells":221},{"EARLY_PHASE1":222,"PHASE1":224,"PHASE2":226,"PHASE3":228,"PHASE4":234,"NA":236},{"trials":223,"activeCount":98},[],{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"trials":229,"activeCount":94,"soonestReadout":68},[230],{"nctId":66,"briefTitle":67,"status":142,"phases":231,"primaryCompletion":68,"completion":68,"start":208,"enrollment":209,"conditions":232,"interventions":233},[88,89],[211],[69,213,214,215],{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":98},[],{"intervention":214,"totalTrials":94,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":252,"NA":254},{"trials":241,"activeCount":98},[],{"trials":243,"activeCount":98},[],{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":94,"soonestReadout":68},[248],{"nctId":66,"briefTitle":67,"status":142,"phases":249,"primaryCompletion":68,"completion":68,"start":208,"enrollment":209,"conditions":250,"interventions":251},[88,89],[211],[69,213,214,215],{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"intervention":215,"totalTrials":94,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":270,"NA":272},{"trials":259,"activeCount":98},[],{"trials":261,"activeCount":98},[],{"trials":263,"activeCount":98},[],{"trials":265,"activeCount":94,"soonestReadout":68},[266],{"nctId":66,"briefTitle":67,"status":142,"phases":267,"primaryCompletion":68,"completion":68,"start":208,"enrollment":209,"conditions":268,"interventions":269},[88,89],[211],[69,213,214,215],{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"intervention":275,"totalTrials":119,"cells":276},"cisplatin",{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":289,"NA":291},{"trials":278,"activeCount":98},[],{"trials":280,"activeCount":98},[],{"trials":282,"activeCount":98},[],{"trials":284,"activeCount":94,"soonestReadout":48},[285],{"nctId":46,"briefTitle":47,"status":142,"phases":286,"primaryCompletion":48,"completion":48,"start":144,"enrollment":145,"conditions":287,"interventions":288},[89],[147,148],[49,150,118],{"trials":290,"activeCount":98},[],{"trials":292,"activeCount":98},[293],{"nctId":294,"briefTitle":295,"status":296,"phases":297,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT00303810","Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma","COMPLETED",[91],"2013-12","2001-01",567,[302],"Brain and Central Nervous System Tumors",[304,275,305,306,307,308,309,310,311],"carboplatin","cyclophosphamide","etoposide phosphate","high-dose chemotherapy","lomustine","methotrexate","thiotepa","vincristine sulfate",{"intervention":59,"totalTrials":119,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":344,"PHASE4":346,"NA":348},{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":119,"soonestReadout":58},[320,330],{"nctId":56,"briefTitle":57,"status":142,"phases":321,"primaryCompletion":58,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":326},[88],"2026-09","2017-08-15",246,[28],[59,327,328,329],"Carfilzomib","Lenalidomide","Dexamethasone",{"nctId":331,"briefTitle":332,"status":166,"phases":333,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":341},"NCT07600151","Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma",[87,88],"2036-09-30","2036-12-31","2026-12-01",220,[339,340],"Myeloma Multiple","Myeloma",[342,59,343],"Etentamig","Bortezomib + Lenalidomide + Dexamethasone",{"trials":345,"activeCount":98},[],{"trials":347,"activeCount":98},[],{"trials":349,"activeCount":98},[],{"intervention":327,"totalTrials":94,"cells":351},{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":353,"activeCount":98},[],{"trials":355,"activeCount":98},[],{"trials":357,"activeCount":94,"soonestReadout":58},[358],{"nctId":56,"briefTitle":57,"status":142,"phases":359,"primaryCompletion":58,"completion":322,"start":323,"enrollment":324,"conditions":360,"interventions":361},[88],[28],[59,327,328,329],{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"intervention":328,"totalTrials":94,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":98},[],{"trials":375,"activeCount":94,"soonestReadout":58},[376],{"nctId":56,"briefTitle":57,"status":142,"phases":377,"primaryCompletion":58,"completion":322,"start":323,"enrollment":324,"conditions":378,"interventions":379},[88],[28],[59,327,328,329],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":94,"soonestReadout":43},[394],{"nctId":41,"briefTitle":42,"status":142,"phases":395,"primaryCompletion":43,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},[88],"2025-10-07","2016-12-21",87,[400],"Bone Marrow Fibrosis",[44],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"intervention":342,"totalTrials":94,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":98},[],{"trials":415,"activeCount":94,"soonestReadout":334},[416],{"nctId":331,"briefTitle":332,"status":166,"phases":417,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":418,"interventions":419},[87,88],[339,340],[342,59,343],{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":98},[],{"intervention":343,"totalTrials":94,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":94,"soonestReadout":334},[434],{"nctId":331,"briefTitle":332,"status":166,"phases":435,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":436,"interventions":437},[87,88],[339,340],[342,59,343],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"intervention":39,"totalTrials":94,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":94,"soonestReadout":38},[452],{"nctId":36,"briefTitle":37,"status":142,"phases":453,"primaryCompletion":38,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":459},[88],"2025-06","2020-05-18",24,[458],"Acute-graft-versus-host Disease",[39],{"trials":461,"activeCount":98},[],{"trials":463,"activeCount":98},[],{"trials":465,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":469,"activeCount":98},[],{"trials":471,"activeCount":98},[],{"trials":473,"activeCount":94,"soonestReadout":73},[474],{"nctId":71,"briefTitle":72,"status":108,"phases":475,"primaryCompletion":73,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},[87,88],"2028-12","2023-06-28",45,[28,480],"Multiple Myeloma in Relapse",[74],{"trials":483,"activeCount":98},[],{"trials":485,"activeCount":98},[],{"trials":487,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[],{"trials":495,"activeCount":94,"soonestReadout":63},[496],{"nctId":61,"briefTitle":62,"status":142,"phases":497,"primaryCompletion":63,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":505},[88],"2026-11-26","2019-11-14",167,[502,503,504],"Acute Myeloid Leukemia in Remission","Acute Lymphoblastic Leukemia in Remission","Myelodysplastic Syndromes",[64],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"intervention":329,"totalTrials":513,"cells":514},4,{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":536,"PHASE4":562,"NA":564},{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":94,"soonestReadout":58},[521,525],{"nctId":56,"briefTitle":57,"status":142,"phases":522,"primaryCompletion":58,"completion":322,"start":323,"enrollment":324,"conditions":523,"interventions":524},[88],[28],[59,327,328,329],{"nctId":526,"briefTitle":527,"status":296,"phases":528,"primaryCompletion":529,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":533},"NCT02977494","Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment",[88],"2021-06","2016-06",22,[28],[534,535,329],"Daratumumab","Bortezomib",{"trials":537,"activeCount":98},[538],{"nctId":539,"briefTitle":540,"status":296,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT01228331","Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL",[88,89],"2019-12","2024-11-20","2010-10",745,[547],"Leukemia",[549,550,551,552,553,329,554,555,556,557,558,559,560,561],"Amsacrine","Clofarabine","Cyclophosphamide","Cytarabine","Daunorubicin hydrochloride","Doxorubicin hydrochloride","Etoposide phosphate","Mercaptopurine","Methotrexate","Methylprednisolone","Pegaspargase","Thioguanine","Vincristine sulfate",{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[566],{"nctId":567,"briefTitle":568,"status":569,"phases":570,"start":571,"enrollment":572,"conditions":573,"interventions":574},"NCT00343369","Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","UNKNOWN",[91],"2003-01",550,[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],"asparaginase","cytarabine","daunorubicin hydrochloride","dexamethasone","doxorubicin hydrochloride","mercaptopurine","pegaspargase","prednisolone","teniposide","thioguanine",{"intervention":54,"totalTrials":94,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":94,"soonestReadout":53},[591],{"nctId":51,"briefTitle":52,"status":108,"phases":592,"primaryCompletion":53,"completion":169,"start":593,"enrollment":456,"conditions":594,"interventions":596},[87],"2024-01-23",[595],"Chronic Hepatitis B",[54,597],"TherVacB",{"trials":599,"activeCount":98},[],{"trials":601,"activeCount":98},[],{"trials":603,"activeCount":98},[],{"trials":605,"activeCount":98},[],{"intervention":597,"totalTrials":94,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":94,"soonestReadout":53},[612],{"nctId":51,"briefTitle":52,"status":108,"phases":613,"primaryCompletion":53,"completion":169,"start":593,"enrollment":456,"conditions":614,"interventions":615},[87],[595],[54,597],{"trials":617,"activeCount":98},[],{"trials":619,"activeCount":98},[],{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"intervention":625,"totalTrials":94,"cells":626},"reboxetine",{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":648},{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[],{"trials":632,"activeCount":98},[],{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[637],{"nctId":638,"briefTitle":639,"status":296,"phases":640,"primaryCompletion":641,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":647},"NCT00853866","Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation",[90],"2009-11","2010-06","2009-01",12,[646],"Cerebral Stroke",[625],{"trials":649,"activeCount":98},[],{"intervention":651,"totalTrials":94,"cells":652},"Chemotherapy",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":673},{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"trials":658,"activeCount":98},[],{"trials":660,"activeCount":98},[],{"trials":662,"activeCount":98},[663],{"nctId":664,"briefTitle":665,"status":569,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT03691441","Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer",[90],"2024-05-05","2018-01-05",280,[671],"Oropharyngeal Cancer",[651],{"trials":674,"activeCount":98},[],{"intervention":676,"totalTrials":94,"cells":677},"Furosemide",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":699},{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[],{"trials":687,"activeCount":98},[688],{"nctId":689,"briefTitle":690,"status":691,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":98,"conditions":695,"interventions":697},"NCT01156220","Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers","WITHDRAWN",[90],"2012-06","2012-01",[696],"Healthy Male and Female Volunteers",[676,698],"aminohippurate sodium",{"trials":700,"activeCount":98},[],{"intervention":698,"totalTrials":94,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":711,"NA":717},{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[713],{"nctId":689,"briefTitle":690,"status":691,"phases":714,"primaryCompletion":693,"completion":693,"start":694,"enrollment":98,"conditions":715,"interventions":716},[90],[696],[676,698],{"trials":718,"activeCount":98},[],{"intervention":720,"totalTrials":94,"cells":721},"Cefuroxime 1,5g",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":745},{"trials":723,"activeCount":98},[],{"trials":725,"activeCount":98},[],{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":98},[732],{"nctId":733,"briefTitle":734,"status":296,"phases":735,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":742},"NCT03141476","Adequacy of Perioperative Cefuroxime Dosage According to the BMI",[90],"2017-11-12","2017-12-12","2017-03-01",60,[741],"Obesity; Drug",[720,743,744],"Cefuroxime 3g","Cefuroxime 4,5g",{"trials":746,"activeCount":98},[],{"intervention":743,"totalTrials":94,"cells":748},{"EARLY_PHASE1":749,"PHASE1":751,"PHASE2":753,"PHASE3":755,"PHASE4":757,"NA":763},{"trials":750,"activeCount":98},[],{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[759],{"nctId":733,"briefTitle":734,"status":296,"phases":760,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":761,"interventions":762},[90],[741],[720,743,744],{"trials":764,"activeCount":98},[],{"intervention":744,"totalTrials":94,"cells":766},{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":781},{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[],{"trials":776,"activeCount":98},[777],{"nctId":733,"briefTitle":734,"status":296,"phases":778,"primaryCompletion":736,"completion":737,"start":738,"enrollment":739,"conditions":779,"interventions":780},[90],[741],[720,743,744],{"trials":782,"activeCount":98},[],{"intervention":784,"totalTrials":94,"cells":785},"Iron",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":808},{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[796],{"nctId":797,"briefTitle":798,"status":296,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":803,"interventions":806},"NCT03036462","Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality",[90],"2024-05-02","2017-03-07",1105,[804,805],"Systolic Heart Failure","Iron Deficiency",[784,807],"Saline",{"trials":809,"activeCount":98},[],{"intervention":807,"totalTrials":94,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":826},{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":98},[],{"trials":819,"activeCount":98},[],{"trials":821,"activeCount":98},[822],{"nctId":797,"briefTitle":798,"status":296,"phases":823,"primaryCompletion":800,"completion":800,"start":801,"enrollment":802,"conditions":824,"interventions":825},[90],[804,805],[784,807],{"trials":827,"activeCount":98},[],{"intervention":829,"totalTrials":94,"cells":830},"Treatment 2 weeks Envarsus followed by 2 weeks Advagraf",{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":850,"NA":852},{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[839],{"nctId":840,"briefTitle":841,"status":296,"phases":842,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":848},"NCT03241043","Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients",[89],"2019-04","2016-05",20,[847],"Liver Transplantation",[829,849],"Treatment 2 weeks Advagraf followed by 2 weeks Envarsus",{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"intervention":849,"totalTrials":94,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":868,"NA":870},{"trials":857,"activeCount":98},[],{"trials":859,"activeCount":98},[],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[864],{"nctId":840,"briefTitle":841,"status":296,"phases":865,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":866,"interventions":867},[89],[847],[829,849],{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":98},[],{"intervention":873,"totalTrials":94,"cells":874},"Diacetylmorphine",{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":895,"NA":897},{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":98},[],{"trials":882,"activeCount":98},[883],{"nctId":884,"briefTitle":885,"status":296,"phases":886,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":893},"NCT00268814","The German Project of Heroin Assisted Treatment of Opiate Dependent Patients",[89],"2003-12","2007-12","2002-03",1015,[892],"Opioid Dependence",[873,894],"Methadone",{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":98},[],{"intervention":894,"totalTrials":94,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":913,"NA":915},{"trials":902,"activeCount":98},[],{"trials":904,"activeCount":98},[],{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[909],{"nctId":884,"briefTitle":885,"status":296,"phases":910,"primaryCompletion":887,"completion":888,"start":889,"enrollment":890,"conditions":911,"interventions":912},[89],[892],[873,894],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"intervention":918,"totalTrials":94,"cells":919},"Melatonin 2mg",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":926,"PHASE4":938,"NA":940},{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[928],{"nctId":929,"briefTitle":930,"status":296,"phases":931,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":937},"NCT02108353","Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers",[89],"2017-03-29","2015-01",46,[936],"Sleep Disorders, Circadian Rhythm",[918],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[],{"intervention":943,"totalTrials":94,"cells":944},"GLP-1",{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":951,"PHASE4":963,"NA":965},{"trials":946,"activeCount":98},[],{"trials":948,"activeCount":98},[],{"trials":950,"activeCount":98},[],{"trials":952,"activeCount":98},[953],{"nctId":954,"briefTitle":955,"status":130,"phases":956,"primaryCompletion":957,"completion":958,"start":959,"enrollment":119,"conditions":960,"interventions":962},"NCT02417103","Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid",[89],"2016-09","2016-12","2011-12",[961],"Obesity",[943],{"trials":964,"activeCount":98},[],{"trials":966,"activeCount":98},[],{"intervention":968,"totalTrials":94,"cells":969},"Tacrolimus",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":990,"NA":992},{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[978],{"nctId":979,"briefTitle":980,"status":296,"phases":981,"primaryCompletion":982,"completion":983,"start":299,"enrollment":984,"conditions":985,"interventions":988},"NCT01429844","Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation",[89],"2007-10","2010-08",274,[986,987],"Bronchiolitis Obliterans","Immunosuppression",[968,989],"Cyclosporine",{"trials":991,"activeCount":98},[],{"trials":993,"activeCount":98},[],{"intervention":989,"totalTrials":94,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[1004],{"nctId":979,"briefTitle":980,"status":296,"phases":1005,"primaryCompletion":982,"completion":983,"start":299,"enrollment":984,"conditions":1006,"interventions":1007},[89],[986,987],[968,989],{"trials":1009,"activeCount":98},[],{"trials":1011,"activeCount":98},[],{"intervention":1013,"totalTrials":94,"cells":1014},"Ranolazine",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1021,"PHASE4":1033,"NA":1035},{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[1023],{"nctId":1024,"briefTitle":1025,"status":296,"phases":1026,"primaryCompletion":1027,"completion":1027,"start":1028,"enrollment":845,"conditions":1029,"interventions":1032},"NCT01797484","Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia",[88,89],"2015-06","2013-08",[1030,1031],"Coronary Artery Disease","Acute Myocardial Ischemia",[1013],{"trials":1034,"activeCount":98},[],{"trials":1036,"activeCount":98},[],{"intervention":1038,"totalTrials":94,"cells":1039},"CMF Chemotherapy",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1058,"NA":1060},{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":98},[1048],{"nctId":1049,"briefTitle":1050,"status":296,"phases":1051,"primaryCompletion":1052,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT01317108","Prognostic and Predictive Impact of uPA\u002FPAI-1",[89],"2008-12","1993-06",689,[1056],"Breast Cancer",[1038],{"trials":1059,"activeCount":98},[],{"trials":1061,"activeCount":98},[],{"intervention":549,"totalTrials":94,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1076,"NA":1078},{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"trials":1069,"activeCount":98},[],{"trials":1071,"activeCount":98},[1072],{"nctId":539,"briefTitle":540,"status":296,"phases":1073,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":1074,"interventions":1075},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"intervention":550,"totalTrials":94,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1094,"NA":1096},{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[1090],{"nctId":539,"briefTitle":540,"status":296,"phases":1091,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":1092,"interventions":1093},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":1095,"activeCount":98},[],{"trials":1097,"activeCount":98},[],{"intervention":558,"totalTrials":94,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1112,"NA":1114},{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[1108],{"nctId":539,"briefTitle":540,"status":296,"phases":1109,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":1110,"interventions":1111},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"intervention":1117,"totalTrials":94,"cells":1118},"Anticoagulation Agents",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1139,"NA":1141},{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[],{"trials":1126,"activeCount":98},[1127],{"nctId":1128,"briefTitle":1129,"status":296,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1137},"NCT04542408","Hamburg Edoxaban for Anticoagulation in COVID-19 Study",[89],"2022-09-06","2023-01-15","2020-11-12",140,[1136],"Covid19",[1117,1138],"Low dose Low molecular weight heparin or Placebo",{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"intervention":1138,"totalTrials":94,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1157,"NA":1159},{"trials":1146,"activeCount":98},[],{"trials":1148,"activeCount":98},[],{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[1153],{"nctId":1128,"briefTitle":1129,"status":296,"phases":1154,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":1134,"conditions":1155,"interventions":1156},[89],[1136],[1117,1138],{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":98},[],{"intervention":1162,"totalTrials":94,"cells":1163},"Allogeneic Stem Cells",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1193,"NA":1195},{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":98},[],{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[1172],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1175,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1180,"interventions":1181},"NCT05675319","Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed \u002F Progressive Patients With Multiple Myeloma After First-line Therapy",[89],"2025-03-14","2025-03-21","2023-03-03",28,[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],"carfilzomib\u002Flenalidomide\u002Fdexamethasone","elotuzumab\u002Flenalidomide\u002Fdexamethasone","daratumumab\u002Fbortezomib\u002Fdexamethasone","daratumumab\u002Flenalidomide\u002Fdexamethasone","ixazomib\u002Flenalidomide\u002Fdexamethasone","pomalidomide\u002Fbortezomib\u002Fdexamethasone","carfilzomib\u002Fdaratumumab\u002Fdexamethasone","Autologous Stem Cells","daratumumab\u002Fpomalidomide\u002Fdexamethasone","isatuximab\u002Fcarfilzomib\u002Fdexamethasone","selinexor\u002Fbortezomib\u002Fdexamethasone",{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[],{"intervention":1182,"totalTrials":94,"cells":1198},{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1211,"NA":1213},{"trials":1200,"activeCount":98},[],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[1207],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1208,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1209,"interventions":1210},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[],{"intervention":1183,"totalTrials":94,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1229,"NA":1231},{"trials":1218,"activeCount":98},[],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[1225],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1226,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1227,"interventions":1228},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"intervention":1184,"totalTrials":94,"cells":1234},{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1239,"PHASE3":1241,"PHASE4":1247,"NA":1249},{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":98},[],{"trials":1242,"activeCount":98},[1243],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1244,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1245,"interventions":1246},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1248,"activeCount":98},[],{"trials":1250,"activeCount":98},[],{"intervention":1185,"totalTrials":94,"cells":1252},{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1259,"PHASE4":1265,"NA":1267},{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[],{"trials":1260,"activeCount":98},[1261],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1262,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1263,"interventions":1264},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"intervention":1186,"totalTrials":94,"cells":1270},{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1283,"NA":1285},{"trials":1272,"activeCount":98},[],{"trials":1274,"activeCount":98},[],{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[1279],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1280,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1281,"interventions":1282},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1284,"activeCount":98},[],{"trials":1286,"activeCount":98},[],{"intervention":1187,"totalTrials":94,"cells":1288},{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1301,"NA":1303},{"trials":1290,"activeCount":98},[],{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":98},[1297],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1298,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1299,"interventions":1300},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[],{"intervention":1188,"totalTrials":94,"cells":1306},{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1319,"NA":1321},{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[1315],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1316,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1317,"interventions":1318},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"intervention":1189,"totalTrials":94,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1337,"NA":1339},{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[1333],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1334,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1335,"interventions":1336},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[],{"intervention":1190,"totalTrials":94,"cells":1342},{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1355,"NA":1357},{"trials":1344,"activeCount":98},[],{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":98},[],{"trials":1350,"activeCount":98},[1351],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1352,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1353,"interventions":1354},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"intervention":1191,"totalTrials":94,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1367,"PHASE4":1373,"NA":1375},{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":98},[],{"trials":1368,"activeCount":98},[1369],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1370,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1371,"interventions":1372},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1374,"activeCount":98},[],{"trials":1376,"activeCount":98},[],{"intervention":1192,"totalTrials":94,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1391,"NA":1393},{"trials":1380,"activeCount":98},[],{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[1387],{"nctId":1173,"briefTitle":1174,"status":130,"phases":1388,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1389,"interventions":1390},[89],[28],[1162,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"intervention":1396,"totalTrials":94,"cells":1397},"Neoadjuvant Nivolumab",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1418,"NA":1420},{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[],{"trials":1405,"activeCount":98},[1406],{"nctId":1407,"briefTitle":1408,"status":569,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1415},"NCT03700905","Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy",[89],"2024-05","2018-08-21",276,[1414],"Head and Neck Cancer",[1396,1416,1417],"Adjuvant Nivolumab","Adjuvant Nivolumab and Ipilimumab",{"trials":1419,"activeCount":98},[],{"trials":1421,"activeCount":98},[],{"intervention":1416,"totalTrials":94,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1436,"NA":1438},{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[],{"trials":1429,"activeCount":98},[],{"trials":1431,"activeCount":98},[1432],{"nctId":1407,"briefTitle":1408,"status":569,"phases":1433,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1434,"interventions":1435},[89],[1414],[1396,1416,1417],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"intervention":1417,"totalTrials":94,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[1450],{"nctId":1407,"briefTitle":1408,"status":569,"phases":1451,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1452,"interventions":1453},[89],[1414],[1396,1416,1417],{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[],{"intervention":1459,"totalTrials":94,"cells":1460},"Alteplase",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1478,"NA":1480},{"trials":1462,"activeCount":98},[],{"trials":1464,"activeCount":98},[],{"trials":1466,"activeCount":98},[],{"trials":1468,"activeCount":98},[1469],{"nctId":1470,"briefTitle":1471,"status":296,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT01525290","Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke",[89],"2018-10","2012-09",501,[17],[1459],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[],{"intervention":1483,"totalTrials":94,"cells":1484},"Gemcitabine neoadjuvant",{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1505,"NA":1507},{"trials":1486,"activeCount":98},[],{"trials":1488,"activeCount":98},[],{"trials":1490,"activeCount":98},[],{"trials":1492,"activeCount":98},[1493],{"nctId":1494,"briefTitle":1495,"status":130,"phases":1496,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1503},"NCT01900327","Neoadjuvant Treatment in Resectable Pancreatic Cancer",[89],"2016-11-22","2017-07","2014-02",32,[1502],"Pancreatic Cancer",[1483,1504],"Gemcitabine adjuvant",{"trials":1506,"activeCount":98},[],{"trials":1508,"activeCount":98},[],{"intervention":1504,"totalTrials":94,"cells":1510},{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1523,"NA":1525},{"trials":1512,"activeCount":98},[],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[],{"trials":1518,"activeCount":98},[1519],{"nctId":1494,"briefTitle":1495,"status":130,"phases":1520,"primaryCompletion":1497,"completion":1498,"start":1499,"enrollment":1500,"conditions":1521,"interventions":1522},[89],[1502],[1483,1504],{"trials":1524,"activeCount":98},[],{"trials":1526,"activeCount":98},[],{"intervention":1528,"totalTrials":94,"cells":1529},"ATG FRESENIUS",{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1534,"PHASE3":1536,"PHASE4":1549,"NA":1551},{"trials":1531,"activeCount":98},[],{"trials":1533,"activeCount":98},[],{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[1538],{"nctId":1539,"briefTitle":1540,"status":296,"phases":1541,"primaryCompletion":1499,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1548},"NCT00678275","Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia",[89],"2015-03","2006-10",161,[1546,1547],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia",[1528,1528],{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[],{"intervention":1554,"totalTrials":94,"cells":1555},"Dapagliflozin 10mg",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1578,"NA":1580},{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[1564],{"nctId":1565,"briefTitle":1566,"status":130,"phases":1567,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1574},"NCT03419624","The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients",[89],"2019-04-01","2019-08-05","2018-02-19",13,[961,1573],"Diabetes Mellitus, Type 2",[1554,1575,1576,1577],"Exenatide 2 mg [Bydureon]","Insulin","Metformin, if taken before",{"trials":1579,"activeCount":98},[],{"trials":1581,"activeCount":98},[],{"intervention":1575,"totalTrials":94,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1590,"PHASE4":1596,"NA":1598},{"trials":1585,"activeCount":98},[],{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[1592],{"nctId":1565,"briefTitle":1566,"status":130,"phases":1593,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1594,"interventions":1595},[89],[961,1573],[1554,1575,1576,1577],{"trials":1597,"activeCount":98},[],{"trials":1599,"activeCount":98},[],{"intervention":1576,"totalTrials":94,"cells":1601},{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1608,"PHASE4":1614,"NA":1616},{"trials":1603,"activeCount":98},[],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[1610],{"nctId":1565,"briefTitle":1566,"status":130,"phases":1611,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1612,"interventions":1613},[89],[961,1573],[1554,1575,1576,1577],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"intervention":1577,"totalTrials":94,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1632,"NA":1634},{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":98},[],{"trials":1627,"activeCount":98},[1628],{"nctId":1565,"briefTitle":1566,"status":130,"phases":1629,"primaryCompletion":1568,"completion":1569,"start":1570,"enrollment":1571,"conditions":1630,"interventions":1631},[89],[961,1573],[1554,1575,1576,1577],{"trials":1633,"activeCount":98},[],{"trials":1635,"activeCount":98},[],{"intervention":1637,"totalTrials":94,"cells":1638},"BIBW 2992",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[1645],{"nctId":1646,"briefTitle":1647,"status":130,"phases":1648,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1654},"NCT01320280","BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer",[88],"2012-11","2011-05",29,[1653],"Refractory Cancer",[1637],{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[],{"intervention":1662,"totalTrials":94,"cells":1663},"Metyrapone",{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[],{"trials":1669,"activeCount":98},[1670],{"nctId":1671,"briefTitle":1672,"status":296,"phases":1673,"completion":1674,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1679},"NCT00125554","Metyrapone as Additive Treatment in Major Depression",[88],"2001-07","1998-05",63,[1678],"Major Depressive Disorder",[1662],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"intervention":1687,"totalTrials":94,"cells":1688},"Sunitinib",{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1690,"activeCount":98},[],{"trials":1692,"activeCount":98},[],{"trials":1694,"activeCount":98},[1695],{"nctId":1696,"briefTitle":1697,"status":296,"phases":1698,"primaryCompletion":1699,"start":1700,"enrollment":531,"conditions":1701,"interventions":1702},"NCT00783653","Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years",[87,88],"2013-07","2008-08",[1546],[1687],{"trials":1704,"activeCount":98},[],{"trials":1706,"activeCount":98},[],{"trials":1708,"activeCount":98},[],{"intervention":1710,"totalTrials":94,"cells":1711},"Revlimid",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":98},[],{"trials":1717,"activeCount":98},[1718],{"nctId":1719,"briefTitle":1720,"status":296,"phases":1721,"primaryCompletion":1722,"completion":298,"start":1723,"enrollment":456,"conditions":1724,"interventions":1725},"NCT00778752","Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma",[87,88],"2013-03","2009-04",[28],[1710],{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[],{"intervention":1733,"totalTrials":94,"cells":1734},"ETIMS",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":98},[1741],{"nctId":1742,"briefTitle":1743,"status":296,"phases":1744,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":26,"conditions":1747,"interventions":1749},"NCT01414634","Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells",[87,88],"2012-10","2010-02",[1748],"Multiple Sclerosis, Relapsing-Remitting",[1733],{"trials":1751,"activeCount":98},[],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"intervention":1757,"totalTrials":94,"cells":1758},"Autologous Hematopoietic Stem Cell Transplantation",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":98},[],{"trials":1764,"activeCount":98},[1765],{"nctId":1766,"briefTitle":1767,"status":130,"phases":1768,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":94,"conditions":1771,"interventions":1773},"NCT04971005","Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial",[88],"2022-02-04","2021-08-27",[1772],"Relapsing-Remitting Multiple Sclerosis",[1757,1774,1775],"Ocrelizumab","Alemtuzumab",{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[],{"intervention":1774,"totalTrials":94,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":98},[],{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[1790],{"nctId":1766,"briefTitle":1767,"status":130,"phases":1791,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":94,"conditions":1792,"interventions":1793},[88],[1772],[1757,1774,1775],{"trials":1795,"activeCount":98},[],{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[],{"intervention":1775,"totalTrials":94,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1812,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[1808],{"nctId":1766,"briefTitle":1767,"status":130,"phases":1809,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":94,"conditions":1810,"interventions":1811},[88],[1772],[1757,1774,1775],{"trials":1813,"activeCount":98},[],{"trials":1815,"activeCount":98},[],{"trials":1817,"activeCount":98},[],{"intervention":138,"totalTrials":94,"cells":1819},{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1821,"activeCount":98},[],{"trials":1823,"activeCount":98},[],{"trials":1825,"activeCount":98},[1826],{"nctId":128,"briefTitle":129,"status":130,"phases":1827,"primaryCompletion":132,"completion":132,"start":133,"enrollment":94,"conditions":1828,"interventions":1829},[88],[135,136],[118,138],{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"intervention":1837,"totalTrials":94,"cells":1838},"PredEver",{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1840,"activeCount":98},[],{"trials":1842,"activeCount":98},[],{"trials":1844,"activeCount":98},[1845],{"nctId":1846,"briefTitle":1847,"status":296,"phases":1848,"primaryCompletion":1849,"completion":1850,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1855},"NCT01862965","Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus",[88],"2018-02-07","2019-03","2013-03-06",38,[1854],"Chronic Graft-versus-host Disease",[1837],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"intervention":1863,"totalTrials":94,"cells":1864},"MVA-SARS-2-S",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[1871],{"nctId":1872,"briefTitle":1873,"status":691,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":98,"conditions":1877,"interventions":1878},"NCT05950776","COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults",[88],"2022-11-02","2021-01-15",[1136],[1863],{"trials":1880,"activeCount":98},[],{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[],{"intervention":1886,"totalTrials":94,"cells":1887},"Adrecizumab",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1905,"PHASE4":1907,"NA":1909},{"trials":1889,"activeCount":98},[],{"trials":1891,"activeCount":98},[],{"trials":1893,"activeCount":98},[1894],{"nctId":1895,"briefTitle":1896,"status":130,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},"NCT05156671","Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial",[88],"2023-08-25","2023-11-15","2022-10-06",16,[1903],"COVID-19",[1886],{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"intervention":1912,"totalTrials":94,"cells":1913},"Boswellic acids",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1929,"PHASE4":1931,"NA":1933},{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[1920],{"nctId":1921,"briefTitle":1922,"status":296,"phases":1923,"primaryCompletion":1924,"completion":1924,"start":1925,"enrollment":1651,"conditions":1926,"interventions":1928},"NCT01450124","Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)",[88],"2014-12","2011-09",[1927],"Relapsing Remitting Multiple Sclerosis",[1912],{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[],{"trials":1934,"activeCount":98},[],{"intervention":534,"totalTrials":94,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[1943],{"nctId":526,"briefTitle":527,"status":296,"phases":1944,"primaryCompletion":529,"completion":529,"start":530,"enrollment":531,"conditions":1945,"interventions":1946},[88],[28],[534,535,329],{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[],{"trials":1952,"activeCount":98},[],{"intervention":535,"totalTrials":94,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"trials":1960,"activeCount":98},[1961],{"nctId":526,"briefTitle":527,"status":296,"phases":1962,"primaryCompletion":529,"completion":529,"start":530,"enrollment":531,"conditions":1963,"interventions":1964},[88],[28],[534,535,329],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[],{"trials":1970,"activeCount":98},[],{"intervention":1972,"totalTrials":94,"cells":1973},"Trifluridine\u002Ftipiracil chemoradiation",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[1980],{"nctId":1981,"briefTitle":1982,"status":130,"phases":1983,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":23,"conditions":1986,"interventions":1988},"NCT04177602","Evaluating Trifluridine\u002FTipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I\u002FII TARC Trial",[87,88],"2022-09-02","2019-11-04",[1987],"Locally Advanced Rectal Cancer",[1972,1989],"Capecitabine based chemoradiation",{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[],{"trials":1995,"activeCount":98},[],{"intervention":1989,"totalTrials":94,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1999,"activeCount":98},[],{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[2004],{"nctId":1981,"briefTitle":1982,"status":130,"phases":2005,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":23,"conditions":2006,"interventions":2007},[87,88],[1987],[1972,1989],{"trials":2009,"activeCount":98},[],{"trials":2011,"activeCount":98},[],{"trials":2013,"activeCount":98},[],{"intervention":2015,"totalTrials":94,"cells":2016},"MVA-SARS-2-ST",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2018,"activeCount":98},[],{"trials":2020,"activeCount":98},[2021],{"nctId":2022,"briefTitle":2023,"status":296,"phases":2024,"primaryCompletion":1875,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2029},"NCT04895449","Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19",[87],"2022-11-08","2021-07-16",43,[1136],[2015],{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[],{"intervention":2039,"totalTrials":94,"cells":2040},"MVA-SARS-2-S vaccinations",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[2045],{"nctId":2046,"briefTitle":2047,"status":296,"phases":2048,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2053},"NCT04569383","Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19",[87],"2021-08-24","2020-10-05",30,[1136],[2039,2054],"Comirnaty",{"trials":2056,"activeCount":98},[],{"trials":2058,"activeCount":98},[],{"trials":2060,"activeCount":98},[],{"trials":2062,"activeCount":98},[],{"intervention":2054,"totalTrials":94,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2073,"PHASE3":2075,"PHASE4":2077,"NA":2079},{"trials":2066,"activeCount":98},[],{"trials":2068,"activeCount":98},[2069],{"nctId":2046,"briefTitle":2047,"status":296,"phases":2070,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":2051,"conditions":2071,"interventions":2072},[87],[1136],[2039,2054],{"trials":2074,"activeCount":98},[],{"trials":2076,"activeCount":98},[],{"trials":2078,"activeCount":98},[],{"trials":2080,"activeCount":98},[],{"intervention":2082,"totalTrials":94,"cells":2083},"MVA-MERS-S_DF1 - Low Dose",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2100,"PHASE3":2102,"PHASE4":2104,"NA":2106},{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":98},[2088],{"nctId":2089,"briefTitle":2090,"status":296,"phases":2091,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":2095,"conditions":2096,"interventions":2098},"NCT04119440","Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS",[87],"2022-11-28","2024-11-06","2021-04-16",145,[2097],"MERS (Middle East Respiratory Syndrome)",[2082,2099],"MVA-MERS-S_DF1 - High Dose",{"trials":2101,"activeCount":98},[],{"trials":2103,"activeCount":98},[],{"trials":2105,"activeCount":98},[],{"trials":2107,"activeCount":98},[],{"intervention":2099,"totalTrials":94,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2118,"PHASE3":2120,"PHASE4":2122,"NA":2124},{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[2114],{"nctId":2089,"briefTitle":2090,"status":296,"phases":2115,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":2095,"conditions":2116,"interventions":2117},[87],[2097],[2082,2099],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"intervention":2127,"totalTrials":94,"cells":2128},"rVSVΔ-ZEBOV-GP",{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2142,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2130,"activeCount":98},[],{"trials":2132,"activeCount":98},[2133],{"nctId":2134,"briefTitle":2135,"status":296,"phases":2136,"primaryCompletion":2137,"completion":2137,"start":2138,"enrollment":2051,"conditions":2139,"interventions":2141},"NCT02283099","Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)",[87],"2015-11","2014-11",[2140],"Hemorrhagic Fever, Ebola",[2127],{"trials":2143,"activeCount":98},[],{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"intervention":305,"totalTrials":513,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2168,"PHASE4":2174,"NA":2176},{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[2158],{"nctId":2159,"briefTitle":2160,"status":296,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":2165,"conditions":2166,"interventions":2167},"NCT03700450","Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma",[88],"2022-11-22","2022-12-01","2018-03-16",37,[28],[551],{"trials":2169,"activeCount":98},[2170],{"nctId":539,"briefTitle":540,"status":296,"phases":2171,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2172,"interventions":2173},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[2178,2182],{"nctId":567,"briefTitle":568,"status":569,"phases":2179,"start":571,"enrollment":572,"conditions":2180,"interventions":2181},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"nctId":294,"briefTitle":295,"status":296,"phases":2183,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2184,"interventions":2185},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":309,"totalTrials":2187,"cells":2188},3,{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2201,"NA":2203},{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"trials":2194,"activeCount":98},[],{"trials":2196,"activeCount":98},[2197],{"nctId":539,"briefTitle":540,"status":296,"phases":2198,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2199,"interventions":2200},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2202,"activeCount":98},[],{"trials":2204,"activeCount":98},[2205,2209],{"nctId":567,"briefTitle":568,"status":569,"phases":2206,"start":571,"enrollment":572,"conditions":2207,"interventions":2208},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"nctId":294,"briefTitle":295,"status":296,"phases":2210,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2211,"interventions":2212},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":311,"totalTrials":2187,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":98},[2223],{"nctId":539,"briefTitle":540,"status":296,"phases":2224,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2225,"interventions":2226},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2228,"activeCount":98},[],{"trials":2230,"activeCount":98},[2231,2235],{"nctId":567,"briefTitle":568,"status":569,"phases":2232,"start":571,"enrollment":572,"conditions":2233,"interventions":2234},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"nctId":294,"briefTitle":295,"status":296,"phases":2236,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2237,"interventions":2238},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":576,"totalTrials":119,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2247,"PHASE4":2253,"NA":2255},{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[2249],{"nctId":539,"briefTitle":540,"status":296,"phases":2250,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2251,"interventions":2252},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2254,"activeCount":98},[],{"trials":2256,"activeCount":98},[2257],{"nctId":567,"briefTitle":568,"status":569,"phases":2258,"start":571,"enrollment":572,"conditions":2259,"interventions":2260},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":577,"totalTrials":119,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2275,"NA":2277},{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[],{"trials":2268,"activeCount":98},[],{"trials":2270,"activeCount":98},[2271],{"nctId":539,"briefTitle":540,"status":296,"phases":2272,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2273,"interventions":2274},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2276,"activeCount":98},[],{"trials":2278,"activeCount":98},[2279],{"nctId":567,"briefTitle":568,"status":569,"phases":2280,"start":571,"enrollment":572,"conditions":2281,"interventions":2282},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":579,"totalTrials":119,"cells":2284},{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2297,"NA":2299},{"trials":2286,"activeCount":98},[],{"trials":2288,"activeCount":98},[],{"trials":2290,"activeCount":98},[],{"trials":2292,"activeCount":98},[2293],{"nctId":539,"briefTitle":540,"status":296,"phases":2294,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2295,"interventions":2296},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2298,"activeCount":98},[],{"trials":2300,"activeCount":98},[2301],{"nctId":567,"briefTitle":568,"status":569,"phases":2302,"start":571,"enrollment":572,"conditions":2303,"interventions":2304},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":580,"totalTrials":119,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2319,"NA":2321},{"trials":2308,"activeCount":98},[],{"trials":2310,"activeCount":98},[],{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":98},[2315],{"nctId":539,"briefTitle":540,"status":296,"phases":2316,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2317,"interventions":2318},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[2323],{"nctId":567,"briefTitle":568,"status":569,"phases":2324,"start":571,"enrollment":572,"conditions":2325,"interventions":2326},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":581,"totalTrials":119,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2341,"NA":2343},{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[2337],{"nctId":539,"briefTitle":540,"status":296,"phases":2338,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2339,"interventions":2340},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[2345],{"nctId":567,"briefTitle":568,"status":569,"phases":2346,"start":571,"enrollment":572,"conditions":2347,"interventions":2348},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":584,"totalTrials":119,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":98},[],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[2359],{"nctId":539,"briefTitle":540,"status":296,"phases":2360,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2361,"interventions":2362},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[2367],{"nctId":567,"briefTitle":568,"status":569,"phases":2368,"start":571,"enrollment":572,"conditions":2369,"interventions":2370},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":555,"totalTrials":119,"cells":2372},{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2379,"PHASE4":2385,"NA":2387},{"trials":2374,"activeCount":98},[],{"trials":2376,"activeCount":98},[],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[2381],{"nctId":539,"briefTitle":540,"status":296,"phases":2382,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":2383,"interventions":2384},[88,89],[547],[549,550,551,552,553,329,554,555,556,557,558,559,560,561],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[2389],{"nctId":294,"briefTitle":295,"status":296,"phases":2390,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2391,"interventions":2392},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":2394,"totalTrials":94,"cells":2395},"Spironolactone",{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2402,"PHASE4":2404,"NA":2406},{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[],{"trials":2401,"activeCount":98},[],{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[2408],{"nctId":2409,"briefTitle":2410,"status":296,"phases":2411,"primaryCompletion":2412,"completion":2412,"start":2413,"enrollment":2414,"conditions":2415,"interventions":2417},"NCT00295347","Mineralocorticoid Receptor in the Treatment of Severe Depression",[91],"2008-06","2005-12",65,[2416],"Major Depression",[2394,2418,2419],"fludrocortisone","escitalopram",{"intervention":2418,"totalTrials":94,"cells":2421},{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[],{"trials":2433,"activeCount":98},[2434],{"nctId":2409,"briefTitle":2410,"status":296,"phases":2435,"primaryCompletion":2412,"completion":2412,"start":2413,"enrollment":2414,"conditions":2436,"interventions":2437},[91],[2416],[2394,2418,2419],{"intervention":2419,"totalTrials":94,"cells":2439},{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"trials":2445,"activeCount":98},[],{"trials":2447,"activeCount":98},[],{"trials":2449,"activeCount":98},[],{"trials":2451,"activeCount":98},[2452],{"nctId":2409,"briefTitle":2410,"status":296,"phases":2453,"primaryCompletion":2412,"completion":2412,"start":2413,"enrollment":2414,"conditions":2454,"interventions":2455},[91],[2416],[2394,2418,2419],{"intervention":2457,"totalTrials":94,"cells":2458},"Treatment 'discontinuation of antidepressant medication'",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2467,"NA":2469},{"trials":2460,"activeCount":98},[],{"trials":2462,"activeCount":98},[],{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":98},[],{"trials":2468,"activeCount":98},[],{"trials":2470,"activeCount":98},[2471],{"nctId":2472,"briefTitle":2473,"status":296,"phases":2474,"primaryCompletion":2475,"completion":2476,"start":2477,"enrollment":2478,"conditions":2479,"interventions":2483},"NCT05191277","Disentangling Pharmacological and Expectation Effects in Antidepressant Discontinuation",[91],"2025-02-26","2025-11-26","2022-08-01",56,[2480,2481,2482],"Depressive Symptoms","Expectations","Antidepressants",[2457,2484],"Treatment 'continuation of antidepressant medication'",{"intervention":2484,"totalTrials":94,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2495,"NA":2497},{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[],{"trials":2498,"activeCount":98},[2499],{"nctId":2472,"briefTitle":2473,"status":296,"phases":2500,"primaryCompletion":2475,"completion":2476,"start":2477,"enrollment":2478,"conditions":2501,"interventions":2502},[91],[2480,2481,2482],[2457,2484],{"intervention":2504,"totalTrials":94,"cells":2505},"Sevoflurane",{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2510,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2507,"activeCount":98},[],{"trials":2509,"activeCount":98},[],{"trials":2511,"activeCount":98},[],{"trials":2513,"activeCount":98},[],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":98},[2518],{"nctId":2519,"briefTitle":2520,"status":296,"phases":2521,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":2525,"interventions":2527},"NCT03522194","Left Ventricular Diastolic Function During Anesthesia Induction",[],"2018-09-27","2017-04-01",200,[2526],"Left Ventricular Diastolic Dysfunction",[2504,2528],"Propofol",{"intervention":2528,"totalTrials":94,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[],{"trials":2538,"activeCount":98},[],{"trials":2540,"activeCount":98},[],{"trials":2542,"activeCount":98},[2543],{"nctId":2519,"briefTitle":2520,"status":296,"phases":2544,"primaryCompletion":2522,"completion":2522,"start":2523,"enrollment":2524,"conditions":2545,"interventions":2546},[],[2526],[2504,2528],{"intervention":575,"totalTrials":94,"cells":2548},{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2550,"activeCount":98},[],{"trials":2552,"activeCount":98},[],{"trials":2554,"activeCount":98},[],{"trials":2556,"activeCount":98},[],{"trials":2558,"activeCount":98},[],{"trials":2560,"activeCount":98},[2561],{"nctId":567,"briefTitle":568,"status":569,"phases":2562,"start":571,"enrollment":572,"conditions":2563,"interventions":2564},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":582,"totalTrials":94,"cells":2566},{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2571,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2568,"activeCount":98},[],{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[],{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[2579],{"nctId":567,"briefTitle":568,"status":569,"phases":2580,"start":571,"enrollment":572,"conditions":2581,"interventions":2582},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":583,"totalTrials":94,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2586,"activeCount":98},[],{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[2597],{"nctId":567,"briefTitle":568,"status":569,"phases":2598,"start":571,"enrollment":572,"conditions":2599,"interventions":2600},[91],[547],[575,305,576,577,578,579,580,309,581,582,583,584,311],{"intervention":304,"totalTrials":94,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2613},{"trials":2604,"activeCount":98},[],{"trials":2606,"activeCount":98},[],{"trials":2608,"activeCount":98},[],{"trials":2610,"activeCount":98},[],{"trials":2612,"activeCount":98},[],{"trials":2614,"activeCount":98},[2615],{"nctId":294,"briefTitle":295,"status":296,"phases":2616,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2617,"interventions":2618},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":307,"totalTrials":94,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2622,"activeCount":98},[],{"trials":2624,"activeCount":98},[],{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[],{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[2633],{"nctId":294,"briefTitle":295,"status":296,"phases":2634,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2635,"interventions":2636},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":308,"totalTrials":94,"cells":2638},{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2647,"NA":2649},{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"trials":2644,"activeCount":98},[],{"trials":2646,"activeCount":98},[],{"trials":2648,"activeCount":98},[],{"trials":2650,"activeCount":98},[2651],{"nctId":294,"briefTitle":295,"status":296,"phases":2652,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2653,"interventions":2654},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":310,"totalTrials":94,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2658,"activeCount":98},[],{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[2669],{"nctId":294,"briefTitle":295,"status":296,"phases":2670,"primaryCompletion":298,"start":299,"enrollment":300,"conditions":2671,"interventions":2672},[91],[302],[304,275,305,306,307,308,309,310,311],{"intervention":2674,"totalTrials":94,"cells":2675},"polyethylene glycol solution for daily bowel lavage.",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2686},{"trials":2677,"activeCount":98},[],{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[],{"trials":2685,"activeCount":98},[],{"trials":2687,"activeCount":98},[2688],{"nctId":2689,"briefTitle":2690,"status":296,"phases":2691,"primaryCompletion":2692,"completion":2693,"start":1650,"enrollment":2694,"conditions":2695,"interventions":2700},"NCT01561248","Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis",[91],"2011-06","2012-02",33,[2696,2697,2698,2699],"Hemolytic Uremic Syndrome","Hemorrhagic Colitis","Intestinal Infectious Disease","Intestinal Infection Due to E. Coli",[2674],{"intervention":2702,"totalTrials":94,"cells":2703},"ziprasidone, sertraline",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2705,"activeCount":98},[],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[],{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[2716],{"nctId":2717,"briefTitle":2718,"status":130,"phases":2719,"primaryCompletion":2720,"completion":642,"start":2721,"enrollment":2722,"conditions":2723,"interventions":2725},"NCT00248261","Ziprasidone and Sertraline in PTSD",[],"2009-08","2005-11",7,[2724],"Post-traumatic Stress Disorder",[2702],{"intervention":2727,"totalTrials":94,"cells":2728},"Opiate Substitution Treatment",{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2733,"PHASE3":2735,"PHASE4":2737,"NA":2739},{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[],{"trials":2738,"activeCount":98},[],{"trials":2740,"activeCount":98},[2741],{"nctId":2742,"briefTitle":2743,"status":296,"phases":2744,"primaryCompletion":1499,"completion":1499,"start":2745,"enrollment":2746,"conditions":2747,"interventions":2748},"NCT01722435","Completion of OST - a Prospective Study",[],"2011-07",78,[892],[2727],{"intervention":2750,"totalTrials":94,"cells":2751},"Remifentanil",{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2756,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2753,"activeCount":98},[],{"trials":2755,"activeCount":98},[],{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[2764],{"nctId":2765,"briefTitle":2766,"status":296,"phases":2767,"primaryCompletion":2768,"completion":2768,"start":2769,"enrollment":2051,"conditions":2770,"interventions":2771},"NCT02429960","Comparison of Different Analgesia-Monitors in Tracing Unconscious Pain Sensations",[91],"2015-09","2015-04",[25],[2750],{"intervention":2773,"totalTrials":94,"cells":2774},"LET gel",{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2783,"NA":2785},{"trials":2776,"activeCount":98},[],{"trials":2778,"activeCount":98},[],{"trials":2780,"activeCount":98},[],{"trials":2782,"activeCount":98},[],{"trials":2784,"activeCount":98},[],{"trials":2786,"activeCount":98},[2787],{"nctId":2788,"briefTitle":2789,"status":296,"phases":2790,"primaryCompletion":2791,"completion":2792,"start":844,"enrollment":2793,"conditions":2794,"interventions":2796},"NCT04378283","Prospective Evaluation of Topical Anesthesia in Children",[91],"2020-02","2020-05",99,[2795],"Skin Lacerations",[2773,2797],"EMLA plus infiltration as anesthetic for wound repair.",{"intervention":2797,"totalTrials":94,"cells":2799},{"EARLY_PHASE1":2800,"PHASE1":2802,"PHASE2":2804,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2801,"activeCount":98},[],{"trials":2803,"activeCount":98},[],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[2812],{"nctId":2788,"briefTitle":2789,"status":296,"phases":2813,"primaryCompletion":2791,"completion":2792,"start":844,"enrollment":2793,"conditions":2814,"interventions":2815},[91],[2795],[2773,2797],{"intervention":2817,"totalTrials":94,"cells":2818},"Open-label placebo",{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[],{"trials":2826,"activeCount":98},[],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[2831],{"nctId":2832,"briefTitle":2833,"status":296,"phases":2834,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":2839,"interventions":2840},"NCT05051995","Combined N-of-1 Trials to Assess Open-Label Placebo Treatment for Antidepressant Discontinuation Symptoms",[91],"2024-02-21","2024-05-15","2022-02-17",25,[2480,2481,2482],[2817],{"intervention":2842,"totalTrials":94,"cells":2843},"Oxytocin",{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2845,"activeCount":98},[],{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[],{"trials":2851,"activeCount":98},[],{"trials":2853,"activeCount":98},[],{"trials":2855,"activeCount":98},[2856],{"nctId":2857,"briefTitle":2858,"status":296,"phases":2859,"primaryCompletion":1474,"completion":1474,"start":694,"enrollment":2860,"conditions":2861,"interventions":2863},"NCT01886014","The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers",[91],80,[2862],"Mechanisms and Modulators of Placebo Analgesia in Healthy Volunteers",[2842],{"intervention":2865,"totalTrials":94,"cells":2866},"Blood Test",{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2868,"activeCount":98},[],{"trials":2870,"activeCount":98},[],{"trials":2872,"activeCount":98},[],{"trials":2874,"activeCount":98},[],{"trials":2876,"activeCount":98},[],{"trials":2878,"activeCount":98},[2879],{"nctId":2880,"briefTitle":2881,"status":296,"phases":2882,"primaryCompletion":1924,"completion":2883,"start":544,"enrollment":2884,"conditions":2885,"interventions":2890},"NCT01317134","Endothelial Function in Patients With Pulmonary Arterial Hypertension",[91],"2016-07",90,[2886,2887,2888,2889],"Hypertension, Pulmonary","Pulmonary Arterial Hypertension","Pathophysiology","Genetics",[2865],{"intervention":2892,"totalTrials":94,"cells":2893},"Gilenya®; Novartis Pharmaceuticals Corporation",{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2900,"PHASE4":2902,"NA":2904},{"trials":2895,"activeCount":98},[],{"trials":2897,"activeCount":98},[],{"trials":2899,"activeCount":98},[],{"trials":2901,"activeCount":98},[],{"trials":2903,"activeCount":98},[],{"trials":2905,"activeCount":98},[2906],{"nctId":2907,"briefTitle":2908,"status":569,"phases":2909,"primaryCompletion":2910,"completion":2911,"start":2912,"enrollment":2913,"conditions":2914,"interventions":2915},"NCT03216915","Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis",[],"2019-12-31","2020-12-31","2013-06-01",100,[30],[2892],{"intervention":2917,"totalTrials":94,"cells":2918},"Continous SAPB",{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2925,"PHASE4":2927,"NA":2929},{"trials":2920,"activeCount":98},[],{"trials":2922,"activeCount":98},[],{"trials":2924,"activeCount":98},[],{"trials":2926,"activeCount":98},[],{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[2931],{"nctId":2932,"briefTitle":2933,"status":296,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":2746,"conditions":2937,"interventions":2941},"NCT05648266","Serratus Plane Block After Minimally Invasive Mitral Valve Repair",[91],"2024-07-01","2022-04-01",[2938,2939,2940],"Minimal Invasive Cardiac Surgery","Minimal Invasive Cardiac Surgery Mitral Valve Surgery","Serratus Anterior Plane Block",[2917]]